About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Ohio | 439 Studies

Clinical Trials Ovarian CancerOhio

Ovarian Cancer Clinical Trials in Ohio

Find 439 clinical trials for ovarian cancer near Ohio. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 81-100 of 439 trials

WithdrawnOvarian Damage in Young Premenopausal Women Undergoing Chemotherapy for CancerRATIONALE: Comparing results of diagnostic procedures, such as ultrasound, done before, during, and after chemotherapy may help doctors learn about the side effects of…NCT00402935·Cleveland, Ohio SuspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsThis phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with…NCT04840589·Bethesda, Maryland and 8 others RecruitingOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerIncyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.NCT05735080·Orlando, Florida and 17 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedAMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CRThis study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects…NCT00770536·Tucson, Arizona and 15 others

CompletedVTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThe purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women…NCT01666444·Phoenix, Arizona and 135 others

TerminatedNM32-2668 in Adult Patients With Selected Advanced Solid TumorsThis is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the…NCT06299163·Birmingham, Alabama and 10 others

Active not recruitingTesting the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerThis phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a…NCT02345265·Phoenix, Arizona and 19 others

RecruitingSolid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingObjective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect…NCT04981119·Gilbert, Arizona and 15 others

CompletedCPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersThis is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in…NCT03454451·Tucson, Arizona and 26 others

Active not recruitingA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerOvarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes.NCT03602859·Anchorage, Alaska and 181 others

CompletedCOM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesPhase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in…NCT04354246·Sarasota, Florida and 8 others

RecruitingStudy of AVZO-021 in Patients With Advanced Solid TumorsThis study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of…NCT05867251·New Haven, Connecticut and 12 others

SuspendedA Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorThis is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed…NCT04042116·Los Angeles, California and 26 others

RecruitingStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in…NCT06819007·Burbank, California and 231 others

CompletedCombination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003322·Birmingham, Alabama and 66 others

UnknownCombination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00017303·Glendale, California and 18 others

CompletedEP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian CancerPrimary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the…NCT01485848·Greenbrae, California and 14 others

CompletedBiomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerThis research trial studies biomarkers in patients with previously untreated invasive ovarian epithelial, fallopian tube, or primary peritoneal cancer.NCT01295489·Hinsdale, Illinois and 8 others

CompletedA Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaA Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer…NCT03395080·Birmingham, Alabama and 16 others

CompletedA Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyThis was a multicenter, open-label extension study.NCT00959647·Scottsdale, Arizona and 9 others

PreviousPage 5 of 22Next

Other Conditions in Ohio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia